ReviewReviews in cardiovascular medicine2025
Anemia and Transfusion in Infective Endocarditis.
Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infective endocarditis (IE) is a severe condition characterized by a predominantly bacterial infection of the heart valves or endocardial surface, often leading to significant morbidity and mortality. Anemia is very common in patients with IE, which may be explained by factors such as chronic inflammation, hemolysis, kidney disease, and pre-existing iron deficiency. This review aimed to comprehensively examine the prevalence, causes, and clinical impact of anemia in IE patients and the role of blood transfusion in managing these patients. The diagnostic approach to anemia in IE includes combining clinical assessment and laboratory investigations, specifically distinguishing between different etiologies. Blood transfusion is likewise very common in IE, especially in surgically treated patients. Thus, balancing the need to correct anemia with the risks associated with blood transfusion is complex, and robust evidence is scarce. Management strategies for anemia in IE may extend beyond transfusion, encompassing pharmacological treatments such as iron supplementation and erythropoiesis-stimulating agents. Despite advancements in understanding the interplay between anemia and IE, several knowledge gaps and unresolved questions remain, necessitating further research to refine treatment protocols and improve patient outcomes. Future directions include investigating emerging therapeutic approaches, optimizing multidisciplinary care pathways, and developing evidence-based guidelines tailored to the unique needs of IE patients. This review underscores the importance of a comprehensive, individualized approach to managing anemia and transfusion in IE, aiming to enhance clinical outcomes and quality of life for affected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.